IVX-A12 Vaccine for Older Adults
What You Need to Know Before You Apply
What is the purpose of this trial?
The primary purpose of the study is to assess the safety, tolerability and immunogenicity of a bivalent respiratory syncytial virus (RSV)/human metapneumovirus (hMPV) virus-like particle (VLP) candidate vaccine (IVX-A12) compared to placebo, when administered as a single-dose regimen in healthy older adults 60 to 85 years of age.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, if you are on treatments that affect the immune system, like certain steroids or immunosuppressive therapies, you might need to stop them 3 months before the vaccination. It's best to discuss your specific medications with the trial team.
How is the IVX-A12 vaccine different from other vaccines for older adults?
The IVX-A12 vaccine is unique because it is specifically designed for older adults, potentially offering a novel approach compared to traditional vaccines that may not elicit a strong immune response in this age group. While the research does not provide direct comparisons, it suggests that IVX-A12 could be an innovative option for enhancing immunity in older populations.12345
What data supports the effectiveness of the IVX-A12 treatment for older adults?
Are You a Good Fit for This Trial?
This trial is for healthy adults aged 60 to 85 who can follow the study procedures for about a year. They should have a stable health condition, even with chronic issues like hypertension or diabetes if well-managed. Women must be unable to conceive. Participants cannot join if they've had recent RSV/hMPV vaccines or infections, are in other trials, have severe liver disease/AIDS/certain cancers, serious vaccine reactions, immune system problems from treatments within the last 3 months.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single intramuscular dose of IVX-A12 or placebo
Follow-up
Participants are monitored for safety and immunogenicity post-vaccination
Extended Follow-up
A subset of participants will be followed for an additional 12 months
What Are the Treatments Tested in This Trial?
Interventions
- IVX-A12
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Icosavax, Inc.
Lead Sponsor